PAINCHEK LTD — Capital/Financing Update 2017

Nov 14, 2017

1

==> picture [194 x 43] intentionally omitted <==

ePAT Technologies Limited ABN 21 146 035 127 Suite 401, 35 Lime Street, Sydney, NSW, 2000 Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008 Phone +61 8 9388 8290 ianhobson@bigpond.com

ASX Release: 15[th] November 2017

PainChek™ Children’s App commercialization timelines on track

ePAT Technologies Ltd can confirm the PainChek™ Apps for infants, toddlers and children are on track to achieve the planned commercialization milestones in 2018.

The company has completed the video library collections for all three age groups, infants (01 years), toddlers (1-3 years) and children (3–12 years).

The videos for the PainChek™ Infant’s facial assessment feature have been coded and these are now being used for modelling and prototype development. The PainChek™ Infant will be the first of the three children’s Apps to be commercialized.

“We believe the PainChek™ Infant App is the ideal market entry point. There are 130 million births worldwide each year and new parents often struggle to learn how to discriminate between pain and other causes of anguish for their child. The PainChek™ Infant App will help address this need” said Philip Daffas, CEO of ePAT Technologies Ltd.

The prototype PainChek™ Infant App is scheduled to be available in Q2 2018 to complete the clinical studies and the regulatory approval processes with commercialization initially in Australia projected in Q4 2018. The PainChek™ Toddler and Children versions will follow closely behind.

“We have successfully addressed many of the technical, clinical and regulatory challenges around facial recognition of pain during this past year with the PainChek™ Dementia App - which is now on the market and gaining positive business traction. We are now taking these learning’s and building on them with our technology partners to deliver the Children’s versions on time” added Daffas.

For further information contact:

Ian Hobson Company Secretary Tel: +61 8 9388 8290

Philip Daffas Managing Director Tel:+61406537235

1

==> picture [194 x 44] intentionally omitted <==

The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.

==> picture [126 x 206] intentionally omitted <==

==> picture [100 x 198] intentionally omitted <==

PainChek™ artificial intelligence assesses facial microexpressions that are indicative of the presence of pain

PainChek™ six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it’s reproducibility, PainChek™ will be able to be used to detect and measure a person’s pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.

==> picture [568 x 108] intentionally omitted <==